The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2019 | Second-generation ALK inhibitors in ALK-positive NSCLC

Name: Second-generation ALK inhibitors in ALK-positive NSCLC
Uploaded: 2019-04-16T15:55:40.000Z
Duration: 42 s
Description: Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, talks about the survival benefits brought by second-generation ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC). This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Antonio Passaro • 16 Apr 2019

ELCC 2019

Lung Cancer Non-Small Cell Lung Cancer Brigatinib

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, talks about the survival benefits brought by second-generation ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC). This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.